Akso Health Group Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Linda Wang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Linda Wang (37 yo)

3.1yrs

Görev süresi

Ms. Yilin Wang also known as Linda, serves as Chief Executive Officer and Chairwoman of the Board at Akso Health Group (formerly known as Xiaobai Maimai Inc.) since October 18, 2021. She served as Co-Chief...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yilin Wang	CEO & Chairwoman of the Board	3.1yrs	Veri yok	Veri yok
Stephen P. Brown	Independent Non-Executive Director	2.6yrs	Veri yok	Veri yok
Wenjuan Liu	Director	3.3yrs	Veri yok	Veri yok
Gerald T. Neal	Independent Non-Executive Director	2.4yrs	Veri yok	Veri yok
Zhe Liu	Independent Non-Executive Director	2.1yrs	Veri yok	Veri yok

2.6yrs

Ortalama Görev Süresi

39yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AHG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Akso Health Group Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Akso Health Group, Annual General Meeting, Apr 30, 2024

Akso Health Group, Annual General Meeting, Jun 19, 2023

Less than half of directors are independent

Less than half of directors are independent

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Now 33% undervalued after recent price drop

Estimating The Intrinsic Value Of Akso Health Group (NASDAQ:AHG)

New major risk - Share price stability

Now 21% undervalued

Now 24% undervalued

Full year 2024 earnings released: US$0.19 loss per share (vs US$0.58 loss in FY 2023)

New minor risk - Financial data availability

Akso Health Group, Annual General Meeting, Apr 30, 2024

AHG Announces Plan to Acquire Online Clinic

Akso Health Group announced that it has received $13.974055 million in funding

Akso Health Group Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.85 loss in FY 2022)

New minor risk - Shareholder dilution

Akso Health Group, Annual General Meeting, Jun 19, 2023

First half 2023 earnings released: EPS: US$0.035 (vs US$0.53 loss in 1H 2022)

Full year 2022 earnings released: US$0.85 loss per share (vs US$1.94 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Akso Health receives non-compliance notice from Nasdaq

Akso Health Group announced delayed 20-F filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Akso Health Group Announces Board Changes

Akso Health Group Announces Board and Committee Changes

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Akso Health Group(NasdaqGM:AHG) dropped from NASDAQ Composite Index

Xiaobai Maimai Eyes Cancer Treatment As E-Commerce Pivot Sputters

New 90-day high: US$2.78

New 90-day high: US$2.67

Hexindai reports 1H results

Hexindai Inc. to Report First Half, 2021 Results on Dec 21, 2020

Hexindai Inc., Annual General Meeting, Dec 16, 2020

Hexindai Inc. Launches Elite Influencers Program on Xiaobai Maimai

Hexindai Inc. announced delayed 20-F filing

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş